These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 19040525)

  • 1. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
    Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
    BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma.
    Miyazaki J; Nishiyama H; Yano I; Nakaya A; Kohama H; Kawai K; Joraku A; Nakamura T; Harashima H; Akaza H
    Anticancer Res; 2011 Jun; 31(6):2065-71. PubMed ID: 21737624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guéin can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group 2, member D ligands.
    Miyazaki J; Kawai K; Kojima T; Oikawa T; Joraku A; Shimazui T; Nakaya A; Yano I; Nakamura T; Harashima H; Akaza H
    BJU Int; 2011 Nov; 108(9):1520-6. PubMed ID: 21314815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New packaging method of mycobacterial cell wall using octaarginine-modified liposomes: enhanced uptake by and immunostimulatory activity of dendritic cells.
    Homhuan A; Kogure K; Akaza H; Futaki S; Naka T; Fujita Y; Yano I; Harashima H
    J Control Release; 2007 Jul; 120(1-2):60-9. PubMed ID: 17467840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    Cancer Gene Ther; 2004 Mar; 11(3):194-207. PubMed ID: 14973549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
    Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
    J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
    Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
    Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
    Yu DS; Lee CF; Hsieh DS; Chang SY
    Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
    Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
    PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
    Vaage J
    Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killed but metabolically active Mycobacterium bovis bacillus Calmette-Guérin retains the antitumor ability of live bacillus Calmette-Guérin.
    Secanella-Fandos S; Noguera-Ortega E; Olivares F; Luquin M; Julián E
    J Urol; 2014 May; 191(5):1422-8. PubMed ID: 24333111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
    Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
    Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological protection induced by bacillus Calmette-Guérin treatment in a murine bladder tumor model.
    Iwasaki A; Kawai K; Hayashi H; Ikeda N; Toida I; Ohtani M; Akaza H
    Int J Urol; 2002 Apr; 9(4):219-24. PubMed ID: 12010317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine.
    Lee CF; Chang SY; Hsieh DS; Yu DS
    J Urol; 2004 Mar; 171(3):1343-7. PubMed ID: 14767345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
    Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
    Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of interleukin-12 against murine bladder cancer.
    Eto M; Harada M; Tamada K; Tokuda N; Koikawa Y; Nakamura M; Nomoto K; Naito S
    J Urol; 2000 May; 163(5):1549-52. PubMed ID: 10751886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.